Precursor B-cell acute lymphoblastic leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:99860OMIM:615545C91.0
Who is this for?
Show terms as
1FDA treatments8Active trials56Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

B-ALLPrecursor B-cell acute lymphoblastic leukemia/lymphomaPrecursor B-cell acute lymphocytic leukemiaPrecursor B-cell acute lymphocytic leukemia/lymphoma
Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Dec 2025Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

The First Affiliated Hospital with Nanjing Medical University — EARLY_PHASE1

TrialNOT YET RECRUITING
Nov 2025CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Peking University People's Hospital — PHASE3

TrialRECRUITING
Apr 2025A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Guangdong Ruishun Biotech Co., Ltd — PHASE1

TrialNOT YET RECRUITING
Jan 2025JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

Tongji Hospital — NA

TrialRECRUITING
Jan 2025Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Hebei Senlang Biotechnology Inc., Ltd. — PHASE2

TrialRECRUITING
Jan 2025NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

The Children's Hospital of Zhejiang University School of Medicine — NA

TrialNOT YET RECRUITING
Nov 2024Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Shandong University

TrialNOT YET RECRUITING
Aug 2024Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

First Affiliated Hospital of Zhejiang University — PHASE2

TrialRECRUITING
Jul 2024The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

Institute of Hematology & Blood Diseases Hospital, China — NA

TrialNOT YET RECRUITING
May 2024Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Miltenyi Biomedicine GmbH — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Besponsa

inotuzumab ozogamicin· Wyeth Pharmaceuticals, LLC■ Boxed WarningOrphan Drug

treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older

View Details →FDA Label ↗

Clinical Trials

8 recruitingView all trials with filters →
Phase 31 trial
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3
Actively Recruiting
· Sites: Beijing, China · Age: 3–79 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 23 trials
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2
Actively Recruiting
· Sites: Hangzhou, Zhejiang · Age: 40–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Phase 2
Actively Recruiting
· Sites: Chengdu, Sichuan · Age: 16–65 yrs
View on ClinicalTrials.gov ↗I'm interested →
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Phase 2
Actively Recruiting
PI: Xiaojun Huang (Peking University People's Hospital) · Sites: Beijing · Age: 3–25 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1
Actively Recruiting
PI: Swati Naik, MD (St. Jude Children's Research Hospital) · Sites: Memphis, Tennessee; Memphis, Tennessee · Age: 0–21 yrs
View on ClinicalTrials.gov ↗I'm interested →
N/A1 trial
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
N/A
Actively Recruiting
PI: Jia Wei, Doctor (Tongji Hospital) · Sites: Wuhan, Hubei · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other1 trial
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
PI: Nirali N Shah, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 3–65 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 56View all specialists →
KM
Kelly W Maloney
Specialist
PI on 1 active trial
ZL
Zhen Li
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
LY
Liuting Yu
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
WW
Wenqing Wang
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
HX
Hongman Xue
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
JI
James Iansavitchous
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
HR
Heidi Rysan
Specialist
2 Precursor B-cell acute lymphoblastic leukemia publications
YC
Yun Chen
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
YX
Yan Xiao
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
HJ
Hao Jiang
ELMHURST, NY
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
KA
Katie Angione
AURORA, CO
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
LS
Leonora R Slatnick
AURORA, CO
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
LH
Lisa Hartman
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
MS
Mia P Sams
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
RD
Rodney P DeKoter
Specialist
2 Precursor B-cell acute lymphoblastic leukemia publications
YT
Yan-Lai Tang
Specialist
1 Precursor B-cell acute lymphoblastic leukemia publication
PS
Prof. Dr. Michael Schmitt
Specialist
PI on 1 active trial
FM
Farhad Ravandi-Kashani, MD
HOUSTON, TX
Specialist
PI on 8 active trials
PK
Prof. Dr. Andreas Kulozik
Specialist
PI on 1 active trial
PM
Paolo Caimi, MD
CLEVELAND, OH
Specialist
PI on 5 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
SM
Steven Devine, MD
LA CROSSE, WI
Specialist
PI on 4 active trials
SM
Susan K. Parsons, MD, MRP
Specialist
PI on 1 active trial
SM
Swati Naik, MD
MEMPHIS, TN
Specialist
PI on 1 active trial
NM
Nirali N Shah, M.D.
Specialist
PI on 7 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Precursor B-cell acute lymphoblastic leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Precursor B-cell acute lymphoblastic leukemiaForum →

No community posts yet. Be the first to share your experience with Precursor B-cell acute lymphoblastic leukemia.

Start the conversation →

Latest news about Precursor B-cell acute lymphoblastic leukemia

2 articles
Clinical trialUNITERAREApr 3, 2026
New Recruiting Trial: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will t…
Clinical trialCLINICALTRIALSMar 26, 2026
Trial Now Recruiting: Orphan Indications for CD19 Redirected Autologous T Cells (NCT04276870)
Researchers are testing a new cancer treatment called CART19 for children and young adults with specific types of blood cancer (B-ALL). The treatment uses the p…
See all news about Precursor B-cell acute lymphoblastic leukemia →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Precursor B-cell acute lymphoblastic leukemia

Are there clinical trials for Precursor B-cell acute lymphoblastic leukemia?

Yes — 8 recruiting clinical trials are currently listed for Precursor B-cell acute lymphoblastic leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Precursor B-cell acute lymphoblastic leukemia?

25 specialists and care centers treating Precursor B-cell acute lymphoblastic leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.